Skip to content

Occipital Nerve Stimulation for the Treatment of Chronic Migraine Headache.

ONSTIM: Occipital Nerve Stimulation for the Treatment of Intractable Migraine.

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00200109
Acronym
ONSTIM
Enrollment
110
Registered
2005-09-20
Start date
2004-05-31
Completion date
2011-05-31
Last updated
2011-10-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Migraine Headache

Brief summary

Background: Medically intractable chronic migraine (CM) is a disabling illness characterized by headache greater than 15 days per month. Method: A multicenter, randomized, blinded, controlled feasibility study was conducted to obtain preliminary safety and efficacy data on occipital nerve stimulation (ONS) in CM. Eligible subjects received an occipital nerve block, and responsers were randomized to adjustable stimulation (AS), preset stimulation (PS) or medical management (MM) groups.

Detailed description

The therapy under investigation involves a Medtronic neurostimulation device which delivers electrical impulses via insulated lead wires placed under the skin near the occipital nerves at the base of the head.

Interventions

Each group had a different plan

Sponsors

MedtronicNeuro
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Diagnosis of Chronic Migraine Headache by International Headache Society (IHS) criteria * compliance with daily questionnaire * headache that has not responded to at least two classes of headache medications * stable headache medication regimen

Exclusion criteria

* previous surgical procedures to disrupt the nerves of the neck relating to the headache * subjects who may require MRI or Diathermy

Design outcomes

Primary

MeasureTime frame
A primary endpoint is not identified for this feasibility study.No primary endpoint

Secondary

MeasureTime frame
Secondary endpoints included: patient daily questionnaire, Migraine Disability Assessment (MIDAS), functional disability, SF-36, acute medication use and subject satisfaction surveys.No secondary endpoint

Countries

Canada, United Kingdom, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026